Tài liệu tham khảo |
Loại |
Chi tiết |
1. Nguyễn Hà Thanh, Vinh PQ. Huyết học Bài giảng sau đại học. Nhà xuất bản Y Học, Hà Nội. 2017;346 |
Sách, tạp chí |
Tiêu đề: |
Nhà xuất bản Y Học, Hà Nội |
Nhà XB: |
Nhà xuất bản Y Học |
|
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. Jan 2019;69(1):7-34 |
Sách, tạp chí |
Tiêu đề: |
CA: a cancer journal for clinicians |
|
4. Cowan AJ, Allen C, Barac A, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA oncology. Sep 1 2018;4(9):1221-1227 |
Sách, tạp chí |
|
5. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. May 28 2009;113(22):5412- 5417 |
Sách, tạp chí |
|
6. Goldstein DA. Denosumab for bone lesions in multiple myeloma - what is its value? Haematologica. May 2018;103(5):753-754 |
Sách, tạp chí |
|
7. Kim DS, Yu ES, Kang KW, et al. Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. The Korean journal of internal medicine. Jul 2017;32(4):711-721 |
Sách, tạp chí |
Tiêu đề: |
The Korean journal of internal medicine |
|
8. Romano A, Parrinello NL, Consoli ML, et al. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Annals of hematology. Nov 2015;94(11):1875-1883 |
Sách, tạp chí |
Tiêu đề: |
Annals ofhematology |
|
9. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. Oct 2008;22(10):1933-1937 |
Sách, tạp chí |
|
10. Iriuchishima H, Saitoh T, Handa H, et al. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. European journal of haematology. Feb 2015;94(2):145-151 |
Sách, tạp chí |
Tiêu đề: |
European journal of haematology |
|
11. Kyle RA, Steensma DP. History of multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2011;183:3-23 |
Sách, tạp chí |
Tiêu đề: |
Recent results incancer research. Fortschritte der Krebsforschung. Progres dans lesrecherches sur le cancer |
|
12. Costa G, Engle RL, Schilling A, et al. Melphalan and prednisone: An effective combination for the treatment of multiple myeloma. The American Journal of Medicine. 1973/05/01/ 1973;54(5):589-599 |
Sách, tạp chí |
Tiêu đề: |
TheAmerican Journal of Medicine |
|
14. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood. Aug 1 1996;88(3):838-847 |
Sách, tạp chí |
|
15. Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood cancer journal. Sep 1 2017;7(9):e600 |
Sách, tạp chí |
Tiêu đề: |
Blood cancer journal |
|
16. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.The oncologist. 2003;8(6):508-513 |
Sách, tạp chí |
|
17. Chen RA, Tu Y, Cao Y, Liu L, Liang Y. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients. The Journal of international medical research.2011;39(5):1975-1984 |
Sách, tạp chí |
Tiêu đề: |
The Journal of international medical research |
|
19. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. May 20 2005;23(15):3412- 3420 |
Sách, tạp chí |
Tiêu đề: |
Journal of clinical oncology : official journal ofthe American Society of Clinical Oncology |
|
20. Raedler LA. Revlimid (Lenalidomide) Now FDA Approved as First- Line Therapy for Patients with Multiple Myeloma. American health &drug benefits. Mar 2016;9(Spec Feature):140-143 |
Sách, tạp chí |
Tiêu đề: |
American health &"drug benefits |
|
21. Perel G, Bliss J, Thomas CM. Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma. P & T : a peer-reviewed journal for formulary management.May 2016;41(5):303-307 |
Sách, tạp chí |
Tiêu đề: |
P & T : a peer-reviewed journal for formulary management |
|
22. Raedler LA. Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma. American health & drug benefits. Mar 2016;9(Spec Feature):111-114 |
Sách, tạp chí |
Tiêu đề: |
Americanhealth & drug benefits |
|
23. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology. Nov 2014;15(12):e538-548 |
Sách, tạp chí |
Tiêu đề: |
The Lancet. Oncology |
|